Tumour Cannabinoid CB1 Receptor and Phosphorylated Epidermal Growth Factor Receptor Expression Are Additive Prognostic Markers for Prostate Cancer

Open Access

Peer-reviewed

Research Article

Tumour Cannabinoid CB₁ Receptor and Phosphorylated Epidermal Growth Factor Receptor Expression Are Additive Prognostic Markers for Prostate Cancer

Christopher J. Fowler ,

* E-mail: cf@pharm.umu.se

Affiliation Department of Pharmacology and Clinical Neuroscience, Pharmacology, Umeå University, Umeå, Sweden
⨯
Peter Hammarsten,

Affiliation Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden
⨯
Anders Bergh

Affiliation Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden
⨯

Prostate cancer
Is the Subject Area "Prostate cancer" applicable to this article?

Thanks for your feedback.
Colorectal cancer
Is the Subject Area "Colorectal cancer" applicable to this article?

Thanks for your feedback.
Cancer detection and diagnosis
Is the Subject Area "Cancer detection and diagnosis" applicable to this article?

Thanks for your feedback.
Diagnostic medicine
Is the Subject Area "Diagnostic medicine" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Cannabinoids
Is the Subject Area "Cannabinoids" applicable to this article?

Thanks for your feedback.
Prostate gland
Is the Subject Area "Prostate gland" applicable to this article?

Thanks for your feedback.
Endocannabinoids
Is the Subject Area "Endocannabinoids" applicable to this article?

Thanks for your feedback.